Related Experiment Video
Updated: Aug 9, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia
Insights
Dexamethasone improved respiratory function in infants with severe bronchopulmonary dysplasia, aiding mechanical ventilation weaning. However, a notable proportion of patients experienced infections during treatment.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Severe bronchopulmonary dysplasia (BPD) poses significant challenges in preterm infants.
- Mechanical ventilation is often required for extended periods in these infants.
- Standard treatments for BPD have limited efficacy, necessitating exploration of novel therapies.
Purpose of the Study:
- To evaluate the efficacy of dexamethasone in infants with severe BPD requiring prolonged mechanical ventilation.
- To assess the impact of dexamethasone on respiratory parameters and ventilator weaning.
- To identify potential adverse effects associated with dexamethasone therapy in this population.
Main Methods:
- A double-blind, crossover, randomized study design was employed.
- Infants with severe BPD (gestational age 27-33 weeks) received either dexamethasone (0.5 mg/kg/day) or placebo for 3 days, followed by a crossover period.
- Respiratory parameters, including respiratory rate, peak inspiratory pressure, and oxygenation, were monitored.
Main Results:
- All six participating infants showed improvement during dexamethasone therapy.
- Significant improvements were observed in ventilator-determined respiratory rate, peak inspiratory pressure, fractional inspired oxygen concentration, and alveolar-arterial oxygen gradients (p < 0.05).
- Dexamethasone expedited the weaning process from mechanical ventilation.
Conclusions:
- Dexamethasone demonstrates a positive effect on respiratory outcomes in infants with severe BPD.
- The study highlights the potential of dexamethasone to facilitate mechanical ventilation weaning.
- A substantial proportion of patients developed infections, indicating a need for careful monitoring of adverse events.
Abstract:
Dexamethasone was compared with placebo in a double-blind, crossover, randomised study of infants with severe bronchopulmonary dysplasia who had required mechanical ventilation for at least four weeks, despite treatment with diuretics, methylxanthines, bronchodilators, fluid restriction, nutritional supplementation, and ligation of the patent ductus arteriosus when indicated. Gestational age ranged from 27 to 33 weeks and birth weight from 800 to 1730 g. Patients received dexamethasone (0 . 5 mg/kg/day) or normal saline for the first 3 days, then treatment was crossed over for the next 3 days. The study was terminated when sequential analysis showed that all six patients had improved during dexamethasone therapy. Significant improvements were seen in ventilator-determined respiratory rate, peak inspiratory pressure, fractional inspired oxygen concentration, and alveolar arterial oxygen gradients (p less than 0 . 05). Although dexamethasone hastened weaning from mechanical ventilation, infection occurred in a substantial proportion of patients.
